Status:
TERMINATED
Long-Term Follow-Up Study of Patients Receiving ATL001
Lead Sponsor:
Achilles Therapeutics UK Limited
Conditions:
Melanoma
Advanced Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847)...
Detailed Description
Up to 90 patients with advanced non-small cell lung cancer ( NSCLC) or metastatic or recurrent melanoma will be enrolled after either: completing 2 years of follow-up visits in study ATX-NS-001 or stu...
Eligibility Criteria
Inclusion
- Patients must have given written informed consent to participate in the study.
- Patients must have received ATL001 in a previous Clinical Trial.
- Patients must be considered, in the opinion of the Investigator, capable of complying with the protocol requirements.
Exclusion
- There are no exclusion criteria.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 18 2023
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04785365
Start Date
June 1 2022
End Date
October 18 2023
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University College London Hospital (UCLH) NHS Foundation Trust, University College Hospital
London, United Kingdom, NW12PG